Cargando…

2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update

Treatment choices for the “severe acute respiratory syndrome‐related coronavirus‐2 (SARS‐CoV‐2)” are inadequate, having no clarity on efficacy and safety profiles. Currently, no established intervention has lowered the mortality rate in the “coronavirus disease 2019 (COVID‐19)” patients. Recently, 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Zoufang, Chavda, Vivek P., Vora, Lalitkumar K., Gajjar, Normi, Apostolopoulos, Vasso, Shah, Nirav, Chen, Zhe-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9041304/
https://www.ncbi.nlm.nih.gov/pubmed/35496298
http://dx.doi.org/10.3389/fphar.2022.899633
_version_ 1784694517700493312
author Huang, Zoufang
Chavda, Vivek P.
Vora, Lalitkumar K.
Gajjar, Normi
Apostolopoulos, Vasso
Shah, Nirav
Chen, Zhe-Sheng
author_facet Huang, Zoufang
Chavda, Vivek P.
Vora, Lalitkumar K.
Gajjar, Normi
Apostolopoulos, Vasso
Shah, Nirav
Chen, Zhe-Sheng
author_sort Huang, Zoufang
collection PubMed
description Treatment choices for the “severe acute respiratory syndrome‐related coronavirus‐2 (SARS‐CoV‐2)” are inadequate, having no clarity on efficacy and safety profiles. Currently, no established intervention has lowered the mortality rate in the “coronavirus disease 2019 (COVID‐19)” patients. Recently, 2-deoxy-D-glucose (2-DG) has evaluated as a polypharmacological agent for COVID-19 therapy owing to its influence on the glycolytic pathway, interaction with viral proteins, and anti-inflammatory action. In May 2020, the Indian drug regulatory authority approved 2-DG as an emergency adjunct therapy in mild to severe COVID-19 patients. Clinical studies of 2-DG corroborate that it aids in faster recovery of hospitalized patients and decreases supplemental oxygen. Herein, we describe the development process, synthesis, mechanism of viral eradication, and preclinical and clinical development of 2-DG and its derivatives as molecularly targeted therapeutics for COVID-19 treatment.
format Online
Article
Text
id pubmed-9041304
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90413042022-04-27 2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update Huang, Zoufang Chavda, Vivek P. Vora, Lalitkumar K. Gajjar, Normi Apostolopoulos, Vasso Shah, Nirav Chen, Zhe-Sheng Front Pharmacol Pharmacology Treatment choices for the “severe acute respiratory syndrome‐related coronavirus‐2 (SARS‐CoV‐2)” are inadequate, having no clarity on efficacy and safety profiles. Currently, no established intervention has lowered the mortality rate in the “coronavirus disease 2019 (COVID‐19)” patients. Recently, 2-deoxy-D-glucose (2-DG) has evaluated as a polypharmacological agent for COVID-19 therapy owing to its influence on the glycolytic pathway, interaction with viral proteins, and anti-inflammatory action. In May 2020, the Indian drug regulatory authority approved 2-DG as an emergency adjunct therapy in mild to severe COVID-19 patients. Clinical studies of 2-DG corroborate that it aids in faster recovery of hospitalized patients and decreases supplemental oxygen. Herein, we describe the development process, synthesis, mechanism of viral eradication, and preclinical and clinical development of 2-DG and its derivatives as molecularly targeted therapeutics for COVID-19 treatment. Frontiers Media S.A. 2022-04-12 /pmc/articles/PMC9041304/ /pubmed/35496298 http://dx.doi.org/10.3389/fphar.2022.899633 Text en Copyright © 2022 Huang, Chavda, Vora, Gajjar, Apostolopoulos, Shah and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Huang, Zoufang
Chavda, Vivek P.
Vora, Lalitkumar K.
Gajjar, Normi
Apostolopoulos, Vasso
Shah, Nirav
Chen, Zhe-Sheng
2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update
title 2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update
title_full 2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update
title_fullStr 2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update
title_full_unstemmed 2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update
title_short 2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update
title_sort 2-deoxy-d-glucose and its derivatives for the covid-19 treatment: an update
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9041304/
https://www.ncbi.nlm.nih.gov/pubmed/35496298
http://dx.doi.org/10.3389/fphar.2022.899633
work_keys_str_mv AT huangzoufang 2deoxydglucoseanditsderivativesforthecovid19treatmentanupdate
AT chavdavivekp 2deoxydglucoseanditsderivativesforthecovid19treatmentanupdate
AT voralalitkumark 2deoxydglucoseanditsderivativesforthecovid19treatmentanupdate
AT gajjarnormi 2deoxydglucoseanditsderivativesforthecovid19treatmentanupdate
AT apostolopoulosvasso 2deoxydglucoseanditsderivativesforthecovid19treatmentanupdate
AT shahnirav 2deoxydglucoseanditsderivativesforthecovid19treatmentanupdate
AT chenzhesheng 2deoxydglucoseanditsderivativesforthecovid19treatmentanupdate